Gene array identification of Epstein Barr virus-regulated cellular genes in EBV-converted Burkitt lymphoma cell lines

Laboratory Investigation

Volumn 82, Issue 11, 2002, Pages 1463-1479

  Baran Marszak, Fanny ^a   Fagard, Remi ^b   Girard, Bernard ^c   Camilleri Broët, Sophie ^d   Zeng, Feng ^a   Lenoir, Gilbert M ^e   Raphaël, Martine ^a   Feuillard, Jean ^a  

^a Service d Hématologie Biologique   (France)

^b UNIVERSITÉ PARIS 13   (France)

^c University Paris I Sorbonne Panthéon   (France)

^d HÔTEL DIEU   (France)

^e INSTITUT GUSTAVE ROUSSY   (France)

Author keywords

[No Author keywords available]

Indexed keywords

BCR ABL PROTEIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; STAT1 PROTEIN; TRANSCRIPTION FACTOR; TUMOR NECROSIS FACTOR RECEPTOR;

APOPTOSIS; ARTICLE; BURKITT LYMPHOMA; CELL CYCLE; CELL FUNCTION; CLUSTER ANALYSIS; CONTROLLED STUDY; DNA MICROARRAY; EPSTEIN BARR VIRUS; GENE CONTROL; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENETIC ANALYSIS; HUMAN; HUMAN CELL; MALIGNANT TRANSFORMATION; NUCLEOTIDE SEQUENCE; PHENOTYPE; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SEQUENCE ANALYSIS; SIGNAL TRANSDUCTION; STATISTICAL ANALYSIS; TRANSCRIPTION REGULATION; VALIDATION PROCESS; VIRUS GENE; VIRUS IDENTIFICATION; WESTERN BLOTTING;

APOPTOSIS; BURKITT LYMPHOMA; CELL CYCLE; CELL LINE, TRANSFORMED; CELL TRANSFORMATION, VIRAL; DNA-BINDING PROTEINS; GENE EXPRESSION REGULATION, NEOPLASTIC; HERPESVIRUS 4, HUMAN; HUMANS; MULTIGENE FAMILY; NF-KAPPA B; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; RECEPTORS, ANTIGEN, B-CELL; STAT1 TRANSCRIPTION FACTOR; TRANS-ACTIVATORS; TUMOR CELLS, CULTURED;

EID: 0036850167     PISSN: 00236837     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.LAB.0000035025.51772.2B     Document Type: Article

References (85)

1. Armitage RJ, Macduff BM, Eisenman J, Paxton R, and Grabstein KH (1995). IL-15 has stimulatory activity for the induction of B cell proliferation and differentiation. J Immunol 154:483-490.
2. Askew DS, Ashmun RA, Simmons BC, and Cleeveland JL (1991). Constitutive c-myc expression in an IL-3-dependant myelöide cell line suppresses cell cycle arrest and accelerates apoptosis. Oncogene 6:1915-1922.
3. Asso Bonnet M, Feuillard J, Ferreira V, Bissieres P, Tarantino N, Korner M, and Raphael M (1998). Relationship between IkappaBalpha constitutive expression, TNFalpha synthesis, and apoptosis in EBV-infected lymphoblastoid cells Oncogene 17:1607-1615.
4. Aubin J, Davi F, Nguyen-Salomon F, Leboeuf D, Debert C, Taher M, Valensi F, Canioni D, Brousse N, Varet B, Flandrin G, and Macintyre EA (1995). Description of a novel FR1 IgH PCR strategy and its comparison with three other strategies for the detection of clonality in B cell malignancies. Leukemia 9:471-479.
5. Auernhammer CJ, Bousquet C, and Melmed S (1999). Auto-regulation of pituitary corticotroph SOCS-3 expression: Characterization of the murine SOCS-3 promoter. Proc Natl Acad Sci USA 96:6964-6969.
6. Beretta L, Gabbay M, Berger R, Hanash SM, and Sonenberg N (1996). Expression of the protein kinase PKR in modulated by IRF-1 and is reduced in 5q-associated leukemias. Oncogene 12:1593-1596.
7. Bertucci F, Van HS, Bernard K, Loriod B, Granjeaud S, Tagett R, Starkey M, Nguyen C, Jordan B, and Birnbaum D (1999). Expression scanning of an array of growth control genes in human tumor cell lines. Oncogene 18:3905-3912.
8. Bhatia P, Taylor WR, Greenberg AH, and Wright JA (1994). Comparison of glyceraldehyde-3-phosphate dehydrogenase and 28S-ribosomal RNA gene expression as RNA loading controls for northern blot analysis of cell lines of varying malignant potential. Anal Biochem 216:223-226.
9. Brockstedt E, Rickers A, Kostka S, Laubersheimer A, Dorken B, Wittmann-Liebold B, Bommert K, and Otto A (1998). Identification of apoptosis-associated proteins in a human Burkitt lymphoma cell line. Cleavage of heterogeneous nuclear ribonucleoprotein A1 by caspase 3. J Biol Chem 273:28057-28064.
10. Bulfone-Pau SS, Bulanova E, Pohl T, Budagian V, Durkop H, Ruckert R, Kunzendorf U, Paus R, and Krause H (1999). Death deflected: IL-15 inhibits TNF-alpha-mediated apoptosis in fibroblasts by TRAF2 recruitment to the IL-15Ralpha chain. FASEB J 13:1575-1585.
11. Caldwell RG, Brown RC, and Longnecker R (2000). Epstein-Barr virus LMP2A-induced B-cell survival in two unique classes of EmuLMP2A transgenic mice. J Virol 74:1101-1113.
12. Caldwell RG, Wilson JB, Anderson SJ, and Longnecker R (1998). Epstein-Barr virus LMP2A drives B cell development and survival in the absence of normal B cell receptor signals. Immunity 9:405-411.
13. Calender A, Billaud M, Aubry JP, Banchereau J, Vuillaume M, and Lenoir GM (1987). Epstein-Barr virus (EBV) induces expression of B-cell activation markers on in vitro infection of EBV-negative B-lymphoma cells. Proc Natl Acad Sci USA 84:8060-8064.
14. Calender A, Cordier M, Billaud M, and Lenoir GM (1990). Modulation of cellular gene expression in B lymphoma cells following in vitro infection by Epstein-Barr virus (EBV). Int J Cancer 46:658-663.
15. Camilleri BS, Davi F, Feuillard J, Seilhean D, Michiels JF, Brousset P, Epardeau B, Navratil E, Mokhtari K, Bourgeois C, Marelle L, Raphael M, and Hauw JJ (1997). AIDS-related primary brain lymphomas: Histopathologic and immunohistochemical study of 51 cases. The French Study Group for HIV-Associated Tumors. Hum Pathol 28:367-374.
16. Chang YE and Laimins LA (2000). Microarray analysis identifies interferon-inducible genes and Stat-1 as major transcriptional targets of human papillomavirus type 31. J Virol 74:4174-4182.
17. Chin YE, Kitagawa M, Su WC, You ZH, Iwamoto Y, and Fu XY (1996). Cell growth arrest and induction of cyclin-dependent kinase inhibitor p21 WAF1/CIP1 mediated by STAT1. Science 272:719-722.
18. Cogswell PC, Scheinman RI, and Baldwin AS (1993). Promoter of the human NF-κB p50/p105 gene. Regulation by NF-κB subunits and by c-REL. J Immunol 150:2794-2804.
19. Cohen JI (2000). Epstein-Barr virus infection. N Engl J Med 343:481-492.
20. Collart MA, Baeuerle P, and Vassalli P (1990). Regulation of tumor necrosis factor alpha transcription in macrophages: Involvement of four kappa B-like motifs and of constitutive and inducible forms of NF-κB. Mol Cell Biol 10:1498-1506.
21. Coller HA, Grandori C, Tamayo P, Colbert T, Lander ES, Eisenman RN, and Golub TR (2000). Expression analysis with oligonucleotide microarrays reveals that MYC regulates genes involved in growth, cell cycle, signaling, and adhesion. Proc Natl Acad Sci USA 97:3260-3265.
22. Cordier-Bussat M, Billaud M, Calender A, and Lenoir GM (1993). Epstein-Barr virus (EBV) nuclear-antigen-2-induced up-regulation of CD21 and CD23 molecules is dependent on a permissive cellular context. Int J Cancer 53:153-160.
23. Cuomo L, Ramquist T, Trivedi P, Wang F, Klein G, Masucci MG (1992). Expression of the Epstein-Barr virus (EBV)-encoded membrane protein LMP1 impairs the in vitro growth, clonability and tumorigenicity of an EBV-negative Burkitt lymphoma line. Int J Cancer 51:949-955.
24. Delibrias CC, Floettmann JE, Rowe M, and Fearon DT (1997). Downregulated expression of SHP-1 in Burkitt lymphomas and germinal center B lymphocytes. J Exp Med 186:1575-1583.
25. Durkop H, Foss HD, Demel G, Klotzbach H, Hahn C, and Stein H (1999). Tumor necrosis factor receptor-associated factor 1 is overexpressed in Reed-Sternberg cells of Hodgkin's disease and Epstein-Barr virus-transformed lymphoid cells. Blood 93:617-623.
26. Eickhoff B, Korn B, Schick M, Poustka A, and van der Bosch J (1999). Normalization of array hybridization experiments in differential gene expression analysis. Nucleic Acids Res 27:e33.
27. Eisen M, Spellman P, Brown P, and Botstein D (1998). Cluster analysis and display of genome-
28. Evan GI, Wyllie AH, Gilbert CS, Littlewood CD, Land H, Brooks M, Waters CM, Penn LZ, and Hancock DC (1992). Induction of apoptosis in fibroblasts by c-myc protein. Cell 69:119-128.
29. Everitt B (1974). Cluster Analysis. London: Heinemann Educ. Books.
30. Feuillard J, Gouy H, Bismuth G, Lee LM, Debre P, and Korner M (1991). NF-κB activation by tumor necrosis factor alpha in the Jurkat T cell line is independent of protein kinase A, protein kinase C, and Ca(2+)-regulated kinases. Cytokine 3:257-265.
31. Feuillard J, Schuhmacher M, Kohanna S, Asso-Bonnet M, Ledeur F, Joubert-Caron R, Bissieres P, Polack A, Bornkamm GW, and Raphael M (2000). Inducible loss of NF-kappaB activity is associated with apoptosis and Bcl-2 down-regulation in Epstein-Barr virus-transformed B lymphocytes. Blood 95:2068-2075.
32. Feuillard J, Taylor D, Casamayor-Palleja M, Johnson GD, and MacLennan IC (1995). Isolation and characteristics of tonsil centroblasts with reference to Ig class switching. Int Immunol 7:121-130.
33. Girdlestone J, Isamat M, Gewert D, and Milstein C (1993). Transcriptional regulation of HLA-A and -B: Differential binding of members of the Rel and IRF families of transcription factors. Proc Natl Acad Sci USA 90:11568-11572.
34. Gires O, Kohlhuber F, Kilger E, Baumann M, Kieser A, Kaiser C, Zeidler R, Scheffer B, Ueffing M, and Hammerschmidt W (1999). Latent membrane protein 1 of Epstein-Barr virus interacts with JAK3 and activates STAT proteins. EMBO J 18:3064-3073.
35. Grant PA, Arulampalam V, Ahrlund-Richter L, and Pettersson S (1992). Identification of Ets-like lymphoid specific elements within the immunoglobulin heavy chain 3′ enhancer. Nucleic Acids Res 20:4401-4408.
36. Gregory CD, Dive C, Henderson S, Smith CA, Williams GT, Gordon J, and Rickinson AB (1991). Activation of Epstein-Barr virus latent genes protects human B cells from death by apoptosis. Nature 14:612-614.
37. Gregory CD, Rowe M, and Rickinson AB (1990). Different Epstein-Barr virus-B cell interactions in phenotypically distinct clones of a Burkitt's lymphoma cell line. J Gen Virol 71:1481-1495.
38. Hatada EN, Naumann M, and Scheidereit C (1993). Common structural constituents confer I kappa B activity to NF-′B p105 and I kappa B/MAD-3. EMBO J 12:2781-2788.
39. Henderson S, Rowe M, Gregory C, Croom-Carter D, Wang F, Longnecker R, Kieff E, and Rickinson A (1991). Induction of bcl-2 expression by Epstein-Barr virus latent membrane protein 1 protects infected B cells from programmed cell death. Cell 65:1107-1115.
40. Henriquez NV, Floettmann E, Salmon M, Rowe M, and Rickinson AB (1999). Differential responses to CD40 ligation among Burkitt lymphoma lines that are uniformly responsive to Epstein-Barr virus latent membrane protein 1. J Immunol 162:3298-3307.
41. Hsieh JJ, Henkel T, Salmon P, Robey E, Peterson MG, and Hayward SD (1996). Truncated mammalian Notch1 activates CBF1/RBPJk-repressed genes by a mechanism resembling that of Epstein-Barr virus EBNA2. Mol Cell Biol 16:952-959.
42. Israel A, Le Bail O, Hatat D, Piette J, Kieran M, Logeat F, Wallach D, Fellous M, and Kourilsky P (1989). TNF stimulates expression of mouse MHC class I genes by inducing an NF kappa B-like enhancer binding activity which displaces constitutive factors. EMBO J 8:3793-3800.
43. Jochner N, Eick D, Zimber-Strobl U, Pawlita M, Bornkamm GW, and Kempkes B (1996). Epstein-Barr virus nuclear antigen 2 is a transcriptional suppressor of the immunoglobulin mu gene: Implications for the expression of the translocated c-myc gene in Burkitt's lymphoma cells. EMBO J 15:375-382.
44. Kang SM, Tran AC, Grilli M, and Lenardo MJ (1992). NF-′B subunit regulation in nontransformed CD4+ T lymphocytes. Science 256:1452-1456.
45. Kempkes B, Spitkovsky D, Jansen-Durr P, Ellwart JW, Kremmer E, Delecluse HJ, Rottenberger C, Bornkamm GW, and Hammerschmidt W (1995). B-cell proliferation and induction of early G1-regulating proteins by Epstein-Barr virus mutants conditional for EBNA2. EMBO J 14:88-96.
46. Kitanaka A, Mano H, Conley ME, and Campana D (1998). Expression and activation of the nonreceptor tyrosine kinase Tec in human B cells. Blood 91:940-948.
47. Kuribara R, Kinoshita T, Miyajima A, Shinjyo T, Yoshihara T, Inukai T, Ozawa K, Look AT, and Inaba T (1999). Two distinct interleukin-3-mediated signal pathways, Ras-NFIL3 (E4BP4 (NF-IL3)) and Bcl-xL, regulate the survival of murine pro-B lymphocytes. Mol Cell Biol 19:2754-2762.
48. Lam EW and La TN (1994). DP and E2F proteins: Coordinating transcription with cell cycle progression. Curr Opin Cell Biol 6:859-866.
49. Lambert PF, Ludford-Menting MJ, Deacon NJ, Kola I, and Doherty RR (1997). The nfkb1 promoter is controlled by proteins of the Ets family. Mol Biol Cell 8:313-323.
50. Leibowicz D (1998). Epstein-Barr virus and a cellular signaling pathway in lymphomas from immunosuppressed patients. N Engl J Med 338:1413-1421.
51. Lin CS, Kuo HH, Chen JY, Yang CS, and Wang WB (2000). Epstein-Barr virus nuclear antigen 2 retards cell growth, induces p21(WAF1) expression, and modulates p53 activity post-translationally. J Mol Biol 303:7-23.
52. Magrath IT, Pizzo PA, Whang-Peng J, Douglass EC, Alabaster O, Gerber P, Freeman CB, and Novikovs L (1980). Characterization of lymphoma-derived cell lines: Comparison of cell lines positive and negative for Epstein-Barr virus nuclear antigen. I Physical, cytogenetic, and growth characteristics. J Natl Cancer Inst 64:465-476.
53. Marks-Konczalik J, Chu SC, and Moss J (1998). Cytokine-mediated transcriptional induction of the human inducible nitric oxide synthase gene requires both activator protein 1 and nuclear factor kappaB-binding sites. J Biol Chem 273: 22201-22208.
54. May MJ and Ghosh S (1997). Rel/NF-κB and I-κB proteins: An overview. Semin Cancer Biol 8:63-73.
55. McDonald PP, Russo MP, Ferrini S, and Cassatella MA (1998). Interleukin-15 (IL-15) induces NF-kappaB activation and IL-8 production in human neutrophils. Blood 92:4828-4835.
56. Miller CL, Burkhardt AL, Lee JH, Stealey B, Longnecker R, Bolen JB, and Kieff E (1995). Integral membrane protein 2 of Epstein-Barr virus regulates reactivation from latency through dominant negative effects on protein-tyrosine kinases. Immunity 2:155-166.
57. Mosialos G, Birkenbach M, Yalamanchili R, VanArsdale T, Ware C, and Kieff E (1995). The Epstein-Barr virus transforming protein LMP1 engages signaling proteins for the tumor necrosis factor receptor family. Cell 80:389-399.
58. Muraille E, Bruhns P, Pesesse X, Daeron M, and Erneux C (2000). The SH2 domain containing inositol 5-phosphatase SHIP2 associates to the immunoreceptor tyrosine-based inhibition motif of Fc gammaRIIB in B cells under negative signaling. Immunol Lett 72:7-15.
59. Naumann M, Nieters A, Hatada EN, and Scheidereit C (1993). NF-κB precursor p100 inhibits nuclear translocation and DNA binding of NF-κB/rel-factors. Oncogene 8:2275-2281.
60. Niculescu AB III, Chen X, Smeets M, Hengst L, Prives C, and Reed SI (1998). Effects of p21(Cip1/Waf1) at both the G1/S and the G2/M cell cycle transitions: Rb is a critical determinant in blocking DNA replication and in preventing endoreduplication [erratum appears in Mol Cell Biol 1998;18(3):1763]. Mol Cell Biol 18:629-643.
61. Ohnishi E, Iwata T, Inouye S, Kurata T, and Sairenji T (1997). Interleukin-4 production in Epstein-Barr virus-transformed B cell lines from peripheral mononuclear cells of patients with atopic dermatitis. J Interferon Cytokine Res 17:597-602.
62. Paul C, Seiliez I, Thissen JP, and Le Cam A (2000). Regulation of expression of the rat SOCS-3 gene in hepatocytes by growth hormone, interleukin-6 and glucocorticoids mRNA analysis and promoter characterization. Eur J Biochem 267: 5849-5857.
63. Rice NR, MacKichan ML, and Israel A (1992). The precursor of NF-κB p50 has I kappa B-like functions. Cell 71:243-253.
64. Rowe M, Peng PM, Huen DS, Hardy R, Croom CD, Lundgren E, and Rickinson AB (1994). Upregulation of bcl-2 by the Epstein-Barr virus latent membrane protein LMP1: A B-cell-specific response that is delayed relative to NF-κB activation and to induction of cell surface markers. J Virol 68:5602-5612.
65. Rowe M, Rowe DT, Gregory CD, Young LS, Farrell PJ, Rupani H, and Rickinson AB (1987). Differences in B cell growth phenotype reflect novel patterns of Epstein-Barr virus latent gene expression in Burkitt's lymphoma cells. EMBO J 6:2743-2751.
66. Ruf IK, Rhyne PW, Yang H, Borza CM, Hutt-Fltcher LM, Cleveland JL, and Sample JT (1999). Epstein-Barr virus regulates c-Myc, apoptosis, and tumorigenicity in Burkitt lymphoma. Mol Cell Biol 19:1651-1660.
67. Savonet V, Maenhaut C, Miot F, and Pirson I (1997). Pitfalls in the use of several "housekeeping" genes as standards for quantitation of mRNA: The example of thyroid cells. Anal Biochem 247:165-167.
68. Shakhov AN, Collart MA, Vassalli P, Nedospasov SA, and Jongeneel CV (1990). Kappa B-type enhancers are involved in lipopolysaccharide-mediated transcriptional activation of the tumor necrosis factor alpha gene in primary macrophages. J Exp Med 171:35-47.
69. Soderberg O, Christiansen I, Nilsson G, Carlsson M, and Nilsson K (1997). Interleukin-15 + thioredoxin induce DNA synthesis in B-chronic lymphocytic leukemia cells but not in normal B cells. Leukemia 11:1298-1304.
70. Strobl LJ, Hofelmayr H, Marschall G, Brielmeier M, Bornkamm GW, and Zimber-Strobl U (2000). Activated Notch1 modulates gene expression in B cells similarly to Epstein-Barr viral nuclear antigen 2. J Virol 74:1727-1735.
71. Strobl LJ, Hofelmayr H, Stein C, Marschall G, Brielmeier M, Laux G, Bornkamm GW, and Zimber SU (1997). Both Epstein-Barr viral nuclear antigen 2 (EBNA2) and activated Notch1 transactivate genes by interacting with the cellular protein RBP-J kappa. Immunobiology 198:299-306.
72. Tang H, Matthes T, Carballido-Perrig N, Zubler RH, and Kindler V (1993). Differential induction of T cell cytokine mRNA in Epstein-Barr virus-transformed B cell clones: Constitutive and inducible expression of interleukin-4 mRNA. Eur J Immunol 23:899-903.
73. Thorley-Lawson D and Babcock G (1999). A model for persistent infection with Epstein-Barr virus of human B cells. Life Sci 65:1433-1453.
74. Tinhofer I, Marschitz I, Henn T, Egle A, and Greil R (2000). Expression of functional interleukin-15 receptor and autocrine production of interleukin-15 as mechanisms of tumor propagation in multiple myeloma. Blood 95:610-618.
75. Tomlinson MG, Kurosaki T, Berson AE, Fujii GH, Johnston JA, and Bolen JB (1999). Reconstitution of Btk signaling by the atypical tec family tyrosine kinases Bmx and Txk. J Biol Chem 274:13577-13585.
76. Torsteinsdottir S, Andersson ML, Avila-Carino J, Ehlin-Henriksson B, Masucci MG, Klein G, and Klein E (1989). Reversion of tumorigenicity and decreased agarose clonability after EBV conversion of an IgH/myc translocation-carrying BL line. Int J Cancer 43:273-278.
77. Wang F, Gregory C, Sample C, Rowe M, Liebowitz D, Murray R, Rickinson A, and Kieff E (1990). Epstein-Barr virus latent membrane protein (LMP1) and nuclear proteins 2 and 3C are effectors of phenotypic changes in B lymphocytes: EBNA-2 and LMP1 cooperatively induce CD23. J Virol 64:2309-2318.
78. Wang YF and Yu-Lee LY (1996). Multiple stat complexes interact at the interferon regulatory factor-1 interferon-gamma activation sequence in prolactin-stimulated Nb2 T cells. Mol Cell Endocrinol 121:19-28.
79. Ward J (1963). Hierarchical grouping to optimize an objective function. J Am Stat Assoc 58:236-244.
80. Williamson BD, Carswell EA, Rubin BY, Prendergast JS, and Old LJ (1983). Human tumor necrosis factor produced by human B-cell lines: Synergistic cytotoxic interaction with human interferon. Proc Natl Acad Sci USA 80:5397-5401.
81. Wood LJ, Mukherjee M, Dolde CE, Xu Y, Maher JF, Bunton TE, Williams JB, and Resar LM (2000). HMG-I/Y, a new c-Myc target gene and potential oncogene. Mol Cell Biol 20:5490-5502.
82. Yen A, Chandler S, and Sturzenegger-Varvayanis S (1991). Regulated expression of the RB "tumor suppressor gene" in normal lymphocyte mitogenesis: Elevated expression in transformed leukocytes and role as a "status quo" gene. Exp Cell Res 192:289-297.
83. Yu CR, Young HA, and Ortaldo JR (1998). Characterization of cytokine differential induction of STAT complexes in primary human T and NK cells. J Leukoc Biol 64:245-258.
84. Zhang Q, Brooks L, Busson P, Wang F, Charron D, Kieff E, Rickinson AB, and Tursz T (1994). Epstein-Barr virus (EBV) latent membrane protein 1 increases HLA class II expression in an EBV-negative B cell line. Eur J Immunol 24:1467-1470.
85. Zhu J and Zhang MQ (2000). Cluster, function and promoter: Analysis of yeast expression array. Symp BioComput, 479-490.